Titre : Chrysosporium

Chrysosporium : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms, Castration-Resistant
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Chrysosporium : Questions médicales les plus fréquentes", "headline": "Chrysosporium : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Chrysosporium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-07", "dateModified": "2025-05-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Chrysosporium" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Deuteromycota", "url": "https://questionsmedicales.fr/mesh/D003904", "about": { "@type": "MedicalCondition", "name": "Deuteromycota", "code": { "@type": "MedicalCode", "code": "D003904", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B01.300.381" } } }, "about": { "@type": "MedicalCondition", "name": "Chrysosporium", "alternateName": "Chrysosporium", "code": { "@type": "MedicalCode", "code": "D002912", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anwei Chen", "url": "https://questionsmedicales.fr/author/Anwei%20Chen", "affiliation": { "@type": "Organization", "name": "College of Resources and Environment, Hunan Agricultural University, Changsha 410128, PR China. Electronic address: A.Chen@hunau.edu.cn." } }, { "@type": "Person", "name": "Liang Hu", "url": "https://questionsmedicales.fr/author/Liang%20Hu", "affiliation": { "@type": "Organization", "name": "School of Minerals Processing and Bioengineering, Key Laboratory of Biohydrometallurgy of Ministry of Education, Central South University, Changsha 410083, China. Electronic address: huliang2018@csu.edu.cn." } }, { "@type": "Person", "name": "Sheng-Tao Yang", "url": "https://questionsmedicales.fr/author/Sheng-Tao%20Yang", "affiliation": { "@type": "Organization", "name": "College of Chemistry and Environment Protection Engineering, Southwest Minzu University, Chengdu, 610041, PR China. Electronic address: yangst@pku.edu.cn." } }, { "@type": "Person", "name": "Ni He", "url": "https://questionsmedicales.fr/author/Ni%20He", "affiliation": { "@type": "Organization", "name": "School of Minerals Processing and Bioengineering, Key Laboratory of Biohydrometallurgy of Ministry of Education, Central South University, Changsha 410083, China." } }, { "@type": "Person", "name": "Motoyuki Shimizu", "url": "https://questionsmedicales.fr/author/Motoyuki%20Shimizu", "affiliation": { "@type": "Organization", "name": "Department of Applied Biological Chemistry, Faculty of Agriculture, Meijo University, Nagoya, Aichi 468-8502, Japan. Electronic address: moshimi@meijo-u.ac.jp." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.", "datePublished": "2022-12-29", "url": "https://questionsmedicales.fr/article/36580184", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10147-022-02288-5" } }, { "@type": "ScholarlyArticle", "name": "Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer.", "datePublished": "2022-09-28", "url": "https://questionsmedicales.fr/article/36171391", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-20319-z" } }, { "@type": "ScholarlyArticle", "name": "Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer.", "datePublished": "2024-08-01", "url": "https://questionsmedicales.fr/article/39150709", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2024.28444" } }, { "@type": "ScholarlyArticle", "name": "CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.", "datePublished": "2024-05-13", "url": "https://questionsmedicales.fr/article/38739593", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0300413" } }, { "@type": "ScholarlyArticle", "name": "[Metastatic castration-resistant prostate cancer-emerging trends in therapy].", "datePublished": "2023-11-13", "url": "https://questionsmedicales.fr/article/37955661", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00120-023-02223-0" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Eucaryotes", "item": "https://questionsmedicales.fr/mesh/D056890" }, { "@type": "ListItem", "position": 3, "name": "Champignons", "item": "https://questionsmedicales.fr/mesh/D005658" }, { "@type": "ListItem", "position": 4, "name": "Deuteromycota", "item": "https://questionsmedicales.fr/mesh/D003904" }, { "@type": "ListItem", "position": 5, "name": "Chrysosporium", "item": "https://questionsmedicales.fr/mesh/D002912" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Chrysosporium - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Chrysosporium", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Chrysosporium", "description": "Comment diagnostiquer une infection par Chrysosporium ?\nQuels tests sont utilisés pour identifier Chrysosporium ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes indiquent une infection par Chrysosporium ?\nPeut-on utiliser des tests sérologiques pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Prostatic+Neoplasms,+Castration-Resistant&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Chrysosporium", "description": "Quels sont les symptômes courants d'une infection fongique ?\nLes infections cutanées par Chrysosporium sont-elles fréquentes ?\nComment se manifestent les infections pulmonaires ?\nLes infections systémiques sont-elles graves ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Prostatic+Neoplasms,+Castration-Resistant&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Chrysosporium", "description": "Comment prévenir les infections par Chrysosporium ?\nLes personnes immunodéprimées doivent-elles prendre des précautions ?\nLe port de gants est-il recommandé lors de manipulations ?\nLes vaccinations aident-elles à prévenir ces infections ?\nL'hygiène personnelle joue-t-elle un rôle dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Prostatic+Neoplasms,+Castration-Resistant&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Chrysosporium", "description": "Quels traitements sont efficaces contre Chrysosporium ?\nLes traitements varient-ils selon la gravité de l'infection ?\nCombien de temps dure le traitement antifongique ?\nDes effets secondaires sont-ils associés aux antifongiques ?\nLes infections par Chrysosporium nécessitent-elles une hospitalisation ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Prostatic+Neoplasms,+Castration-Resistant&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Chrysosporium", "description": "Quelles complications peuvent survenir avec Chrysosporium ?\nLes infections par Chrysosporium peuvent-elles être mortelles ?\nComment les complications sont-elles gérées ?\nLes complications affectent-elles le pronostic ?\nLes infections récurrentes sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Prostatic+Neoplasms,+Castration-Resistant&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Chrysosporium", "description": "Quels sont les principaux facteurs de risque d'infection ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection fongique ?\nLes traitements immunosuppresseurs sont-ils un facteur de risque ?\nLes voyages dans des zones tropicales augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Prostatic+Neoplasms,+Castration-Resistant&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par Chrysosporium ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen microscopique et la culture du champignon." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour identifier Chrysosporium ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de culture et des techniques moléculaires comme la PCR peuvent être utilisés." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biopsies peuvent être nécessaires pour confirmer l'infection fongique." } }, { "@type": "Question", "name": "Quels symptômes indiquent une infection par Chrysosporium ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des lésions cutanées, des infections pulmonaires ou systémiques." } }, { "@type": "Question", "name": "Peut-on utiliser des tests sérologiques pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sérologiques ne sont généralement pas fiables pour Chrysosporium." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une infection fongique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, toux, éruptions cutanées et fatigue." } }, { "@type": "Question", "name": "Les infections cutanées par Chrysosporium sont-elles fréquentes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent provoquer des lésions cutanées et des démangeaisons." } }, { "@type": "Question", "name": "Comment se manifestent les infections pulmonaires ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles se manifestent par une toux persistante, des douleurs thoraciques et des difficultés respiratoires." } }, { "@type": "Question", "name": "Les infections systémiques sont-elles graves ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être graves et nécessitent une attention médicale immédiate." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de l'état immunitaire." } }, { "@type": "Question", "name": "Comment prévenir les infections par Chrysosporium ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter l'exposition à des environnements humides et à des matériaux contaminés aide à prévenir." } }, { "@type": "Question", "name": "Les personnes immunodéprimées doivent-elles prendre des précautions ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles doivent éviter les environnements à risque et consulter un médecin régulièrement." } }, { "@type": "Question", "name": "Le port de gants est-il recommandé lors de manipulations ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le port de gants lors de la manipulation de terre ou de matériaux potentiellement contaminés est conseillé." } }, { "@type": "Question", "name": "Les vaccinations aident-elles à prévenir ces infections ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Non, il n'existe pas de vaccin spécifique contre les infections par Chrysosporium." } }, { "@type": "Question", "name": "L'hygiène personnelle joue-t-elle un rôle dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne hygiène personnelle peut réduire le risque d'infections fongiques." } }, { "@type": "Question", "name": "Quels traitements sont efficaces contre Chrysosporium ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les antifongiques comme l'itraconazole et le voriconazole sont souvent utilisés." } }, { "@type": "Question", "name": "Les traitements varient-ils selon la gravité de l'infection ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections légères peuvent être traitées par voie orale, tandis que les cas graves nécessitent une perfusion." } }, { "@type": "Question", "name": "Combien de temps dure le traitement antifongique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement peut varier de plusieurs semaines à plusieurs mois selon la gravité." } }, { "@type": "Question", "name": "Des effets secondaires sont-ils associés aux antifongiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des nausées, des éruptions cutanées et des problèmes hépatiques peuvent survenir." } }, { "@type": "Question", "name": "Les infections par Chrysosporium nécessitent-elles une hospitalisation ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend de la gravité de l'infection; les cas graves peuvent nécessiter une hospitalisation." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Chrysosporium ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections systémiques graves et des lésions pulmonaires." } }, { "@type": "Question", "name": "Les infections par Chrysosporium peuvent-elles être mortelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en particulier chez les personnes immunodéprimées, elles peuvent être fatales." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent souvent des traitements antifongiques intensifs et un suivi médical." } }, { "@type": "Question", "name": "Les complications affectent-elles le pronostic ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la présence de complications peut aggraver le pronostic et prolonger la durée de traitement." } }, { "@type": "Question", "name": "Les infections récurrentes sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections récurrentes peuvent survenir, surtout chez les patients immunodéprimés." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'immunodépression, le diabète et l'exposition à des environnements humides." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un risque accru en raison d'un système immunitaire affaibli." } }, { "@type": "Question", "name": "Le diabète augmente-t-il le risque d'infection fongique ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut affaiblir le système immunitaire et augmenter le risque d'infections." } }, { "@type": "Question", "name": "Les traitements immunosuppresseurs sont-ils un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements immunosuppresseurs augmentent le risque d'infections fongiques." } }, { "@type": "Question", "name": "Les voyages dans des zones tropicales augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyages dans des zones tropicales peuvent exposer à des agents pathogènes fongiques." } } ] } ] }

Sources (10000 au total)

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.

Enzalutamide is effective against castration-resistant prostate cancer (CRPC). However, it is unclear which patients would benefit more from enzalutamide treatment. Here, we analyzed patients who rece... We retrospectively analyzed 101 patients treated with enzalutamide for CRPC at our institution. As primary endpoints we regarded the prostate-specific antigen (PSA) response rate and PSA-progression-f... PSA reductions of ≥ 50% and ≥ 90% were observed in 78 (77%) and 47 (47%) patients, respectively, compared with the baseline. During the follow-up period, 67 (66%) patients showed PSA progression, with... Time to CRPC and lymph node metastasis were predictors of the PSA response rate and PSA-PFS....

Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer.

Abiraterone acetate and enzalutamide are recommended as preferred treatments for metastatic castration-resistant prostate cancer (mCRPC), but differences in their relative efficacy are unclear due to ... To compare clinical outcomes in patients with mCRPC treated with abiraterone acetate or enzalutamide.... This retrospective, multicenter cohort study included patients with mCRPC in the US Department of Veterans Affairs health care system who initiated treatment with abiraterone acetate or enzalutamide b... Abiraterone acetate or enzalutamide.... The study used inverse probability of treatment weighting to balance baseline characteristics between patients initiating abiraterone acetate or enzalutamide and evaluated restricted mean survival tim... The study included 5779 patients (median age, 74.42 years [IQR, 68.94-82.14 years]). Median follow-up was between 38 and 60 months. Patients initiating enzalutamide on average had longer OS than those... In this cohort study of patients with mCRPC, initiation of enzalutamide was associated with small but statistically significant improvements in OS, PCS, TTS, and TTR compared with initiation of abirat...

[Metastatic castration-resistant prostate cancer-emerging trends in therapy].

An increasing understanding of the cellular processes involved in growth, metastasis and development of resistance enable the development of new treatment strategies for advanced prostate cancer.... Using selected examples, the aim of this report is to present current developments to the reader and to give an outlook on possible upcoming changes in the treatment of advanced prostate cancer.... Narrative report based on expert consensus, supported by a literature search in PubMed (MEDLINE) and the abstract databases of the American Society of Clinical Oncology (ASCO) and European Society of ... The androgen receptor (AR) signal transduction pathway remains a focus of scientific interest. Androgen synthesis inhibitors and AR degraders are promising new approaches to overcome resistance mediat... New treatment strategies give hope that we will be able to intervene even more effectively in the course of disease of advanced prostate cancer in the future. However, a major challenge, especially fo...

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.

Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including... MAGNITUDE (ClinicalTrials.gov identifier: NCT03748641) is a phase III, randomized, double-blinded study that evaluates niraparib and abiraterone acetate plus prednisone (niraparib + AAP) in patients w... Median rPFS in the... Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP.... [Media: see text]....

Efficacy of Enzalutamide Rechallenge for Metastatic Castration-Resistant Prostate Cancer.

There have been several reports on rechallenge with docetaxel, cabazitaxel, abiraterone acetate, or ethinylestradiol for metastatic castration-resistant prostate cancer (mCRPC). However, the efficacy ... We retrospectively reviewed 63 consecutive patients who received enzalutamide for mCRPC at our institution between 2014 and 2022. Eight of these patients underwent rechallenge with enzalutamide after ... PSA decline to enzalutamide rechallenge was observed in 6 patients (75%), of which 2 patients had a PSA response. The median treatment duration was 4 months (range 1-12) and median PSA progression-fre... Enzalutamide rechallenge achieved a PSA response in a quarter of our patients with mCRPC after disease progression on prior enzalutamide. However, no improvement of OS was identified in these patients...

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance.

Mammalian Target of rapamycin (mTOR) plays a central role in regulating cell growth, proliferation, and cell cycle. The key component of mTORC2 is highly expressed in docetaxel-resistant prostate cell... A docetaxel-resistant human prostate cell line (PC-3/DTX) was constructed to investigate the role of mTORC2 in docetaxel resistance. The lentivirus was transfected into cells to knock down the express... Docetaxel showed the lowest IC... We investigated the role of mTORC2 signaling on the acquired docetaxel -resistant PC-3 cells to identify potential methods for clinical treatment. MTORC2 expression is essential for docetaxel drug res...

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance.

To investigate underlying mechanism of JMJD2A in regulating cytoskeleton remodeling in castration-resistant prostate cancer (CRPC) resistant to docetaxel.... Tissue samples from CRPC patients were collected, and the expression of JMJD2A, miR-34a and cytoskeleton remodeling-related proteins were evaluated by qPCR, western blot and immunohistochemistry, and ... In clinical experiment, the CRPC-resistant group showed higher expression of JMJD2A, STMN1, α-Tubulin, β-Tubulin and F-actin, and lower expression of miR-34a and β3-Tubulin compared to the sensitive g... JMJD2A promoted docetaxel resistance in prostate cancer cells by regulating cytoskeleton remodeling through the miR-34a/STMN1/β3-Tubulin axis....